Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DVA, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Heparin | Kidney Failure, Chronic | Phase 3 · NCT02651428 | Completed |
| Neutrolin | Kidney Failure, Chronic | Phase 3 · NCT02651428 | Completed |
| Pentoxifylline | Hypoalbuminemia | Phase 3 · NCT00561093 | Completed |
| FMX-8 | Anemia of Chronic Disease | Phase 2 · NCT01873534 | Terminated |
| Thymalfasin | COVID-19 | Phase 2 · NCT04428008 | Completed |
| Cavosonstat | Drug Interaction Potentiation | Phase 1 · NCT02500667 | Completed |
| Nalbuphine | Uremic Pruritus | Phase 1 · NCT02373215 | Completed |
Also used in these trials (approved or third-party drugs, not DVA's own candidates): Calcium Acetate, Lanthanum Carbonate, Sevelamer Carbonate, Elbasvir And Grazoprevir, Rifampin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
DVA holds $604.7M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DVA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Warren E. Buffett | 5%+ holder (13D) | 35,892,479 | 57.06% | 2025-02-11 |
| BERKSHIRE HATHAWAY INC 10% owner |
Insider | 28,314,666 | 45.02% | 2026-10-27 |
| Javier Rodriguez Chief Executive Officer, Director · +56,506 options |
Insider | 840,408 | 1.34% | 2026-06-15 |
| Joel Ackerman CFO and Treasurer · +15,427 options |
Insider | 132,434 | 0.21% | 2026-05-07 |
| Kathleen Alyce Waters Chief Legal & Pub. Affairs Off · +8,610 options |
Insider | 109,194 | 0.17% | 2026-06-15 |
| David Paul Maughan Chief Operating Officer, DKC · +14,351 options |
Insider | 86,604 | 0.14% | 2026-09-22 |
| Pamela M Arway Director |
Insider | 27,223 | 0.04% | 2026-08-15 |
| James O Hearty Chief Compliance Officer · +3,050 options |
Insider | 22,389 | 0.04% | 2026-05-14 |
| Christopher Michael Berry Chief Accounting Officer |
Insider | 19,640 | 0.03% | 2026-03-15 |
| Barbara J Desoer Director |
Insider | 14,299 | 0.02% | 2026-08-15 |
| Phyllis R Yale Director |
Insider | 9,803 | 0.02% | 2026-08-15 |
| Gregory J. Moore Director |
Insider | 8,091 | 0.01% | 2026-08-15 |
Share count 62,900,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DVA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →